INVESTOR NOTICE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

INVESTOR NOTICE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Robbins Geller Rudman & Dowd LLP SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”), have until Monday, August 10, 2026 to seek appointment as lead plaintiff of the Erasca class action lawsuit.

Captioned Cheng v. Erasca, Inc. , No. 26-cv-03481 (S.D. Cal.), the Erasca class action lawsuit charges Erasca as well as certain of Erasca’s top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Erasca class action lawsuit, please provide your information here: https://www.rgrdlaw.com/cases-erasca-inc-class-action-lawsuit-eras.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected] .

CASE ALLEGATIONS : Erasca is a clinical-stage precision oncology company that focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

Erasca’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors.

The Erasca class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk of violating patent and trade secret protections; and (ii) based on the foregoing, the defendants lack...